Greco-Hainsworth Centers for Research
The Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) is Tennessee Oncology’s dedicated clinical research division.
GHCR is named to honor Drs. Anthony Greco and John Hainsworth, who, as a part of Tennessee Oncology, founded Sarah Cannon Research Institute in 1993 and changed cancer research by beginning a legacy of expanding access to clinical trial options in community oncology practices, close to where patients live, and improving heath equity.
About The Greco-Hainsworth Centers for Research
GHCR equips Tennessee Oncology researchers with a broad menu of clinical trial opportunities in all phases of drug development, radiation oncology, proton trials and CAR-T therapy. It also opens the door to studies examining access to clinical research, supportive care services, care delivery innovation and the impact of social determinants of health.
With the launch of GHCR, Tennessee Oncology is expanding its trial offerings to all of its 35 sites of care . Because of the practice’s expansive care footprint, researchers will be able to examine the impact of clinical research in both urban and rural regions. The center also partners with like-minded peers in broader medical and academic communities to share research and work collectively on initiatives that advance cancer care and improve patients’ lives.
Ian W. Flinn, MD, PhD
Chief Scientific Officer
Dr. Flinn is a Tennessee Oncology Physician with more than 700 scientific publications. He is the former Director of Blood Cancer at Sarah Cannon Research Institute. Prior to that, Dr. Flinn was an associate professor of oncology at Johns Hopkins University, where he also received his PhD in Clinical Investigations and conducted his Clinical Fellowship in Oncology and Hematology.
Director of Research Operations
With over two decades of experience in clinical research operations, Askew has worked in community-based and academic research institutions, as well as in clinical operations and global program management roles at research, biotechnology, and biopharmaceutical organizations. Most recently, she served as the Senior Director of Clinical Operations at NiKang Therapeutics.